Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

MadeMed vs Steady State Health

Two GLP-1 desks, one scoreboard. We put MadeMed and Steady State Health head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 8 · Grade B

MadeMed

Visit MadeMed Full brief →
vs
No. 404 · Grade C

Steady State Health

Visit Steady State Health Full brief →

The verdict

MadeMed takes this head-to-head.

MadeMed scores 86 to 55 on our six-factor Brief Score — Publishes a price for every dose of every route — which makes it easy to brief, and expensive if you stay low.

That doesn't make Steady State Health a bad call — it's best for readers who want women in oregon or washington wanting glp-1 within perimenopause and menopause care. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
92
40
Supply Reliability
84
73
Transparency
94
43
Access Breadth
76
36
Clinical Oversight
84
70
Track Record
82
74
MadeMedBrief Score 86 · 55Steady State Health

Price, coverage & the tracker

MadeMedSteady State Health
Brief Score86/100 (B)55/100 (C)
Semaglutide$239/mo injectable · $219/mo sublingual (quarterly)Not disclosed
Tirzepatide$399/mo injectable · $299/mo sublingual (quarterly)Not disclosed
Coverage40 states2 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

MadeMed: Publishes one price per route that holds at every dose — the cleanest dose-to-price mapping we track.

Steady State Health: New to the tracker on 1 August 2026. This program publishes no monthly medication price, so there is no line for us to track until it does.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.